Aortic aneurysm: AU screening, surveillance and repair thresholds

Aortic aneurysm is one of those diagnoses that most patients never know they have until it is found incidentally on imaging, discovered during opportunistic screening, or presents as a catastrophic emergency. The abdominal aortic aneurysm (AAA) is by far the most common type, occurring in approximately 5% of men aged 65 or older, particularly those with a smoking history. It kills through rupture, which carries pre-hospital mortality of around 50%. The clinically important news is that surveillance is straightforward, modifiable risk can be meaningfully reduced, and elective repair is safe and durable. The role of general practice is to identify who needs screening, arrange and interpret surveillance, manage modifiable risk aggressively, and recognise — including in subtle presentations — the symptoms that demand urgent vascular review.

A. Core clinical — the AU general practice framework

Definitions

An abdominal aortic aneurysm (AAA) is a permanent focal dilation of the infrarenal aorta to ≥3.0 cm in diameter (the normal calibre is approximately 2.0 cm). The infrarenal segment — below the origin of the renal arteries — accounts for approximately 75% of all aortic aneurysms. Juxtarenal and suprarenal aneurysms involve or extend above the renal vessels and are more surgically complex.

A thoracic aortic aneurysm (TAA) is defined as ascending aorta ≥4.0 cm or descending aorta ≥3.5 cm. Thoracic aneurysms are more commonly associated with genetic connective tissue disorders and bicuspid aortic valve than with smoking or atherosclerosis.

Aortic dissection is a distinct entity — a tear in the aortic intima allowing blood to track within the aortic wall. It is not synonymous with aneurysm, though both may coexist in Marfan syndrome or Loeys-Dietz syndrome, where the aortic wall is inherently fragile.

Who is at risk

The ANZSVS and Heart Foundation Australia identify the following risk profile for AAA:

Modifiable factors:

• Smoking — the dominant modifiable risk factor; relative risk approximately five times that of never-smokers. Continued smoking accelerates aneurysm expansion by approximately 25%.
• Hypertension — sustained uncontrolled blood pressure contributes to aneurysm wall stress and expansion.
• Hyperlipidaemia — atherosclerosis is the principal biological mechanism behind non-genetic AAA.

Non-modifiable factors:

• Male sex — men are approximately four times more likely to develop AAA than women.
• Age ≥65 — prevalence approximately 5% in Australian men aged 65 or older.
• Family history — a first-degree relative with AAA confers approximately tenfold increased risk; screening is recommended for relatives from age 50–55.
• Ethnicity — higher prevalence in people of European background; lower in Aboriginal and Torres Strait Islander populations, though overall cardiovascular risk burden is very high in this group.

Genetic and syndromic causes (predominantly thoracic):

• Marfan syndrome (FBN1 mutation) — aortic root dilatation; TAA; dissection risk even at smaller diameters.
• Loeys-Dietz syndrome (TGFBR1/2 mutations) — aggressive aortopathy; lower repair thresholds than non-syndromic disease.
• Vascular Ehlers-Danlos syndrome type IV (COL3A1) — arterial fragility; elective repair often avoided given catastrophic complication risk.
• Bicuspid aortic valve — aortopathy occurs in approximately 30% even with a competent valve; surveillance indicated.

Clinical presentation and recognition

The vast majority of aortic aneurysms are asymptomatic until rupture or until they reach a very large size. Most are found incidentally on imaging ordered for another reason — renal ultrasound, CT abdomen, or echocardiogram. Active recognition through screening and systematic surveillance is what prevents rupture.

When symptoms do occur:

• Vague, intermittent abdominal or back discomfort may indicate expansion, impending rupture, or an inflammatory AAA.
• Distal embolisation — blue toe syndrome, livedo reticularis from shedding of mural thrombus.
• A pulsatile abdominal mass is palpable in only 30–40% of patients even at 5 cm; sensitivity falls further in patients with a high BMI.

Ruptured AAA should be considered in any patient aged 60 or older presenting with sudden, severe abdominal, back, or flank pain — particularly with hypotension or collapse. The classic triad of pain, hypotension, and pulsatile abdominal mass is present in fewer than 50% of cases. Ruptured AAA is frequently misdiagnosed as renal colic, musculoskeletal back pain, or acute diverticulitis; a high index of suspicion is essential in the appropriate demographic.

Investigations

Abdominal ultrasound is the first-line investigation — accurate, safe, radiation-free, and Medicare-rebatable (item range 55036–55278). It is the modality of choice for both initial screening and ongoing surveillance.

CT angiography (CTA) provides the anatomical detail required for pre-operative planning and is the emergency investigation of choice when rupture is suspected in a haemodynamically stable patient.

MRI / MRA is an alternative when contrast or radiation must be minimised (e.g., advanced chronic kidney disease, repeated surveillance in a young patient with connective tissue disorder).

Echocardiogram (MBS item 55113) is appropriate for aortic root and valve assessment when a thoracic aneurysm is suspected.

Genetic testing (FBN1, TGFBR1/2, COL3A1) is indicated in patients presenting under age 50, those with a strong family history without an identified syndrome, or those with phenotypic features suggesting a heritable connective tissue disorder. Refer to clinical genetics.

B. Surveillance intervals and repair thresholds

ESVS 2024 guidelines provide the internationally adopted framework for AAA surveillance, and ANZSVS practice follows these closely:

AAA diameter	Management
under 3.0 cm	Not aneurysmal; routine cardiovascular risk management
3.0–3.9 cm (small)	Abdominal ultrasound every 3 years
4.0–4.9 cm (moderate)	Abdominal ultrasound every 12 months
5.0–5.4 cm (large)	Abdominal ultrasound every 3–6 months; vascular surgery assessment
≥5.5 cm men / ≥5.0 cm women	Refer vascular surgery for elective repair

Rapid expansion — more than 5 mm in six months or more than 10 mm in a year — warrants urgent vascular surgery referral regardless of absolute size.

Symptomatic AAA — abdominal, back, or flank pain attributable to the aneurysm — requires urgent vascular surgery referral regardless of size.

The lower repair threshold in women (5.0 cm vs 5.5 cm in men) reflects observational data showing women have a higher rupture risk per unit of diameter.

EVAR — endovascular aneurysm repair

EVAR is the modern first-line approach for most infrarenal AAAs with suitable anatomy. A stent-graft is delivered through the femoral arteries under fluoroscopic guidance, lining and excluding the aneurysm sac without a large abdominal incision. Perioperative mortality is approximately 1–2% at experienced centres, compared with 3–5% for open repair. Recovery is substantially faster, and EVAR is feasible in patients who are at higher surgical risk for open repair.

The critical limitation of EVAR is the requirement for lifelong surveillance imaging — typically CT or duplex ultrasound annually — to detect endoleak (persistent blood flow into the excluded aneurysm sac). Type I and III endoleaks require reintervention; type II endoleaks (retrograde flow from lumbar or inferior mesenteric arteries) are monitored. EVAR is not appropriate when anatomy is unfavourable: a short or angulated aortic neck, tortuous iliac vessels, or juxta/suprarenal involvement.

Open repair

Open aortic repair remains the definitive technique for patients with anatomy unsuitable for EVAR, younger patients where lifelong durability is the priority, and complex aneurysms requiring suprarenal aortic clamping. Perioperative mortality is approximately 3–5% at experienced centres. Recovery requires six to eight weeks from a major laparotomy and aortic reconstruction. The major advantage over EVAR is durability — once healed, no ongoing aneurysm-specific imaging surveillance is required.

Ruptured AAA — emergency management

Suspected ruptured AAA demands immediate emergency response. If the patient is haemodynamically unstable, call 000 and arrange direct transfer to a centre with vascular surgery capability — do not delay for imaging in an unstable patient. Permissive hypotension (target systolic blood pressure approximately 80–90 mmHg) limits haemorrhage before surgical control. CT angiography is appropriate only if the patient is haemodynamically stable. Both EVAR and open repair are used for ruptured AAA; the IMPROVE trial demonstrated equivalent overall outcomes, with the approach determined by anatomy and centre capability.

C. Optimal medical therapy for any AAA

Regardless of aneurysm size or repair status, all patients with a known AAA require eTG- and Heart Foundation Australia-endorsed optimal cardiovascular medical therapy:

Smoking cessation is the single most important intervention — in any patient with an AAA who smokes, cessation discussion is warranted at every encounter. Smoking accelerates expansion by ~25% and substantially raises rupture risk. NPS MedicineWise endorses combination pharmacotherapy — nicotine replacement therapy, varenicline, or bupropion — with behavioural support. Varenicline and bupropion are PBS Authority-listed. Referral to the Quitline (13 78 48) is free and accessible from anywhere in Australia.

Blood pressure control targeting below 130/80 mmHg is standard per cardiovascular guidelines. There is no evidence that beta-blockers specifically reduce AAA expansion in non-syndromic patients (though atenolol or losartan are standard in Marfan syndrome). ACE inhibitors, ARBs, CCBs, or thiazide diuretics are appropriate depending on comorbidities and tolerability; choice follows standard hypertension management.

High-intensity statin therapy (atorvastatin or rosuvastatin) is recommended for cardiovascular risk reduction; LDL-C targets follow standard dyslipidaemia guidelines. Both are PBS General Schedule.

Antiplatelet therapy — low-dose aspirin (100 mg daily) — is appropriate where calculated cardiovascular risk supports its use. It does not specifically prevent AAA growth but is standard in the cardiovascular risk profile typical of AAA patients. PBS General Schedule.

Lifestyle — Mediterranean dietary pattern, regular moderate aerobic exercise, BMI management, and alcohol within national guidelines — supports overall cardiovascular risk reduction. Patients with moderate or large aneurysms should discuss heavy lifting and exertion limits with their vascular surgeon; sustained high-load resistance exercise or Valsalva strain may transiently raise intra-aortic pressure.

No medications have been proven to halt AAA growth directly. Doxycycline and roxithromycin showed initial biological plausibility but did not demonstrate meaningful benefit in randomised trials.

D. Australian operations

MBS items

MBS Online lists the following items relevant to AAA care:

Item	Context
699 — Heart Health Check	For patients ≥30 (≥18 for ATSI); practical opportunity to assess cardiovascular risk and discuss AAA screening eligibility
707 — 75+ Health Assessment	Annual comprehensive; include AAA history, surveillance scheduling, fitness to drive
715 — ATSI Health Assessment	Comprehensive cardiovascular risk; selective AAA discussion based on individual risk factors
55036–55278	Abdominal ultrasound — Medicare-rebatable for AAA screening and surveillance
55113	Echocardiogram — for aortic root / TAA assessment, pre-operative cardiac workup
965/967 — GPCCMP	Chronic vascular disease management; replaced items 721/723 from 1 July 2025

PBS medications

Per PBS and AMH: antihypertensives (ACEi/ARB, beta-blocker, CCB, thiazide) and statins (atorvastatin, rosuvastatin) are General Schedule. Aspirin 100 mg is General Schedule or OTC. Smoking cessation pharmacotherapy — varenicline (Champix) and bupropion — requires Authority (Streamlined). Nicotine replacement therapy is OTC.

Specialist pathways

Vascular surgery services for AAA are available at major metropolitan hospitals and, increasingly, via telehealth (ANZSVS) for regional and rural patients reviewing surveillance results. EVAR is performed at tertiary and major district centres; complex fenestrated/branched EVAR for juxta/suprarenal anatomy is limited to high-volume tertiary vascular centres. Cardiothoracic surgery for TAA, and clinical genetics for syndromic aortopathy, are available at major hospitals.

Driving

Austroads Assessing Fitness to Drive 2022 provides guidance for patients post-AAA repair, including stricter requirements for commercial vehicle licence holders. Document all discussions and any restrictions recommended in the medical record.

E. Special populations

Marfan syndrome and connective tissue disorders. TAA in Marfan syndrome requires elective repair at a lower threshold than non-syndromic patients (ascending aortic root ≥5.0 cm, or lower when additional high-risk features are present). Beta-blockade (atenolol) and/or ARB (losartan) are standard in Marfan syndrome to slow aortic root dilatation — both have good supporting evidence. Strenuous contact sports, heavy resistance exercise, and activities causing prolonged Valsalva strain should be avoided. Pregnancy in a person with Marfan syndrome and aortic root >4.0 cm carries substantial risk of aortic dissection; pre-conception counselling with specialist cardiology and maternal-fetal medicine is essential.

Older and frail patients. As AAA diameter increases, the balance between rupture risk and operative risk shifts — and in patients with significant frailty, severe cardiopulmonary disease, or limited life expectancy, conservative management with ongoing medical optimisation may be the most appropriate approach. Shared decision-making, ideally involving the vascular surgeon, the GP, and the patient (and their family or substitute decision-maker), is essential. Patient preferences about quality of life and major surgery should guide the discussion.

Women. AAA prevalence in women is approximately 1% (compared with ~5% in men aged ≥65), but women with AAA have a higher rupture risk per millimetre of diameter — which explains the lower elective repair threshold (≥5.0 cm vs ≥5.5 cm in men). Opportunistic screening is appropriate in women with both a family history of AAA and a significant smoking history.

Post-EVAR care. After EVAR, annual or biennial imaging surveillance is required indefinitely to detect late endoleak, stent-graft migration, or limb occlusion. GP records should note this surveillance requirement and prompt review if imaging becomes overdue. Contrast CT is the gold standard; duplex ultrasound is acceptable for routine annual follow-up at experienced centres.

When to escalate

Refer to vascular surgery when:

• AAA diameter reaches or approaches the repair threshold (≥5.5 cm men, ≥5.0 cm women).
• Rapid expansion on surveillance (>5 mm in 6 months, >10 mm in a year).
• New symptoms that may be attributable to the aneurysm — urgent referral.
• Suspected rupture — emergency activation, call 000; do not delay imaging in an unstable patient.
• Post-EVAR surveillance revealing endoleak, expansion, or structural concerns.
• Patient requesting information about surgical options.

Refer to cardiothoracic surgery for TAA at or approaching the repair threshold, or for any patient with syndromic aortopathy and progressive dilatation.

Refer to clinical genetics for patients presenting under age 50, strong family history without an established diagnosis, or clinical features suggesting a heritable connective tissue disorder.

What this article is and is not

This is general health information drawn from current Australian and international vascular surgery and cardiovascular guidelines — ANZSVS, ESVS 2024, USPSTF 2019, Heart Foundation Australia, eTG, AMH, CSANZ, RANZCR — updated in line with Australian general practice standards. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about screening eligibility, surveillance intervals, surgical timing, medical therapy, and activity restrictions are made individually with a treating GP and specialist.

For trusted patient resources: HealthDirect — Aortic aneurysm, Heart Foundation, ANZSVS patient information.

If sudden severe abdominal or back pain, collapse, or marked dizziness occurs — call 000 immediately.

---

Sources cited

1. ANZSVS — Australian and New Zealand Society for Vascular Surgery
2. ESVS 2024 Clinical Practice Guidelines on Abdominal Aorto-iliac Artery Aneurysms
3. USPSTF 2019 — Abdominal Aortic Aneurysm Screening
4. Heart Foundation Australia
5. Therapeutic Guidelines (eTG) — Cardiovascular
6. Australian Medicines Handbook
7. CSANZ — Cardiac Society of Australia and New Zealand
8. HealthDirect — Aortic aneurysm
9. RANZCR — Royal Australian and New Zealand College of Radiologists
10. MBS Online
11. PBS — Pharmaceutical Benefits Schedule
12. Austroads — Assessing Fitness to Drive 2022
13. NPS MedicineWise — Smoking cessation